Followers | 144 |
Posts | 27707 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Saturday, March 28, 2015 7:06:42 AM
25-Mar-2015
Annual Report
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
Management's Discussion and Analysis of Financial Condition and Results of Operations analyzes the major elements of our balance sheets, statements of income and cash flows. This section should be read in conjunction with the other sections of this Annual Report on Form 10-K for the year ended December 31, 2014 and our financial statements and accompanying notes to these financial statements. All amounts are in U.S. dollars and rounded.
Description of Business
We are a clinical-stage biopharmaceutical company focused on developing therapeutic products for the treatment of ophthalmic disorders. We have in-licensed certain patents and patent applications protecting the use in the ophthalmic field of our current pipeline drug under development, a synthetic A3 adenosine receptor, or A3AR, agonist, CF101 (known generically as IB-MECA). CF101 is currently being developed by us to treat two ophthalmic indications:
glaucoma and uveitis. We are currently conducting a Phase II trial with respect to the development of CF101 for the treatment of glaucoma or related syndromes of ocular hypertension.
CF101 is a highly-selective, orally bioavailable small molecule synthetic drug, which targets the A3AR. We believe that CF101 has a favorable safety profile and a potent anti-inflammatory activity, mediated via its capability to inhibit the production of inflammatory cytokines, such as TNF-?, MMPs, IL-1, and IL-6. This is mediated by activation of the A3AR, which is highly expressed in inflammatory tissues in contrast to normal tissues where expression levels of the receptor are very low. We believe that the anti-inflammatory and neuro-protective effects of CF101 make it a candidate for use in the treatment of ophthalmic indications.
We are focused on the development of CF101 for the treatment of glaucoma, with a Phase II study ongoing in Israel and Europe. We recently amended the ongoing Phase II study protocol and continue to the second cohort, where patients will be treated with 2 mg CF101 or placebo. This decision is based on positive data from the psoriasis Phase II/III study currently conducted with CF101 by our majority stockholder and parent, Can-Fite. As a result, there will not be an interim analysis and the full study data is expected to be announced in mid-2015. If successful, the treatment of glaucoma with an oral drug has the potential to be a breakthrough treatment in resolving patient compliance issues with current topical treatments. A third-party validation for the utilization of A3 adenosine receptor agonists for lowering intraocular pressure and treating glaucoma has been recently published by Professor M. Francesca Cordeiro, a Professor of Glaucoma & Retinal Neuro-degeneration at the University College of London and Imperial College in London.
According to GlobalData, the global market for glaucoma drugs is estimated to exceed $3 billion by 2018 and the global uveitis therapeutics market is expected to grow from $0.3 billion in 2010 to $1.6 billion by 2017. None of our product candidates have been approved for sale or marketing and, to date, there have been no commercial sales of any of our product candidates.
Recent MIGI News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/18/2024 09:48:55 PM
- Mawson Infrastructure Group Inc. Announces Monthly Operational Update for August 2024 • GlobeNewswire Inc. • 09/16/2024 10:01:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 10:00:16 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/11/2024 10:09:01 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/10/2024 10:10:20 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 09:05:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/09/2024 09:05:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/05/2024 01:26:21 PM
- Mawson Infrastructure Group Expands to Ohio for AI/HPC Expansion • GlobeNewswire Inc. • 08/27/2024 12:50:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/27/2024 12:48:56 PM
- Mawson Infrastructure Group Inc. Announces Monthly Operational Update for July 2024 • GlobeNewswire Inc. • 08/22/2024 12:50:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/22/2024 12:48:25 PM
- Mawson Infrastructure Group Inc. Reports Q2 2024 Financial Results • GlobeNewswire Inc. • 08/19/2024 09:15:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/19/2024 09:15:10 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/19/2024 08:57:21 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2024 08:30:02 PM
- Mawson Infrastructure Group Inc. to Join World Summit AI (Artificial Intelligence) in October 2024 • GlobeNewswire Inc. • 08/14/2024 12:30:18 PM
- Mawson Infrastructure Group Inc. Expands into AI and HPC Markets and Announces the Signing of AI/HPC Colocation Agreement for 20 MW • GlobeNewswire Inc. • 08/12/2024 12:45:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 12:45:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 09:00:35 PM
- Mawson Infrastructure Group Inc. to Present at the 2024 Gateway Conference in San Francisco, CA • GlobeNewswire Inc. • 08/06/2024 12:45:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/18/2024 09:02:41 PM
- Mawson Infrastructure Group Inc. Announces Monthly Operational Update for June 2024 • GlobeNewswire Inc. • 07/18/2024 08:53:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2024 08:46:03 PM
- Mawson Infrastructure Group Announces Several Recent New Hires to Further Drive Transformation and Growth Initiatives • GlobeNewswire Inc. • 07/17/2024 08:45:17 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM